Serum Ferritin and Vitamin D in Female Hair Loss: Do They Play a Role?Rasheed H.a · Mahgoub D.a · Hegazy R.a · El-Komy M.a · Abdel Hay R.a · Hamid M.A.a · Hamdy E.b
Departments of aDermatology and bClinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Aim: Evaluation of serum ferritin and vitamin D levels in females with chronic telogen effluvium (TE) or female pattern hair loss (FPHL), in order to validate their role in these common hair loss diseases. Methods: Eighty females (18 to 45 years old) with hair loss, in the form of TE or FPHL, and 40 age-matched females with no hair loss were included in the study. Diagnosis was based upon clinical examination as well as trichogram and dermoscopy. Serum ferritin and vitamin D2 levels were determined for each participant. Results: Serum ferritin levels in the TE (14.7 ± 22.1 μg/l) and FPHL (23.9 ± 38.5 μg/l) candidates were significantly lower than in controls (43.5 ± 20.4 μg/l). Serum vitamin D2 levels in females with TE (28.8 ± 10.5 nmol/l) and FPHL (29.1 ± 8.5 nmol/l) were significantly lower than in controls (118.2 ± 68.1 nmol/l; p < 0.001). These levels decreased with increased disease severity. Serum ferritin cut-off values for TE and FPHL were 27.5 and 29.4 μg/l, respectively, and those for vitamin D were 40.9 and 67.9 nmol/l. Conclusion: Low serum ferritin and vitamin D2 are associated with hair loss in females with TE and FPHL. Screening to establish these levels in cases of hair loss and supplementing with them when they are deficient may be beneficial in the treatment of disease.
© 2013 S. Karger AG, Basel
- Mounsey AL, Reed SW: Diagnosing and treating hair loss. Am Fam Physician 2009;80:356-362.
- Shrivastava SB: Diffuse hair loss in an adult female: approach to diagnosis and management. Indian J Dermatol Venereol Leprol 2009;75:20-27.
- Hard S: Non-anemic iron deficiency as an etiologic factor in diffuse loss of hair of the scalp in women. Acta Derm Venereol 1963;43:562-569.
- Bregy A, Trueb RM: No association between serum ferritin levels >10 microg/l and hair loss activity in women. Dermatology 2008;217:1-6.
- Olsen EA, Reed KB, Cacchio PB, Caudill L: Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010;63:991-999.
- Moeinvaziri M, Mansoori P, Holakooee K, Safaee Naraghi Z, Abbasi A: Iron status in diffuse telogen hair loss among women. Acta Dermatovenerol Croat 2009;17:279-284.
- Deloche C, Bastien P, Chadoutaud S, Galan P, Bertrais S, Hercberg S, de Lacharrière O: Low iron stores: a risk factor for excessive hair loss in non-menopausal women. Eur J Dermatol 2007;17:507-512.
- Trost LB, Bergfeld WF, Calogeras E: The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006;54:824-844.
- Rushton DH, Ramsay ID: The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992;36:421-427.
- Kantor J, Kessler LJ, Brooks DG, Cotsarelis G: Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003;121:985-988.
- Rushton DH: Decreased serum ferritin and alopecia in women. J Invest Dermatol 2003;121:xvii-xviii.
- Sinclair R: There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002;147:982-984.
- Kennedy A, Kohn M, Lammi A, Clarke S: Iron status and haematological changes in adolescent female inpatients with anorexia nervosa. J Paediatr Child Health 2004;40:430-432.
- Heldenberg D, Tenenbaum G, Weisman Y: Effect of iron on serum 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D concentrations. Am J Clin Nutr 1992;56:533-536.
- Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, Kiss I, Lakatos P, Marton A, Molnar MZ, Nemeth Z, Szabo A, Mucsi I: Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 2010;117:c373-c378.
- Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M: Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-776.
- Tsiaras WG, Weinstock MA: Factors influencing vitamin D status. Acta Derm Venereol 2011;91:115-124.
- Wang J, Lu Z, Au JL: Protection against chemotherapy-induced alopecia. Pharm Res 2006;23:2505-2514.
- De Lacharrière O, Deloche C, Misciali C, Piraccini BM, Vincenzi C, Bastien P, Tardy I, Bernard BA, Tosti A: Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol 2001;137:641-646.
- Tosti A, Torres F: Dermoscopy in the diagnosis of hair and scalp disorders. Actas Dermosifiliogr 2009;100:114-119.
- Tisma VS, Poljak-Blazi M: The role of oxidative stress and iron in pathophysiology of Rosacea. Lijec Vjesn 2011;133:288-291.
- Baraka MA, Steurbaut S, Laubach M, Coomans D, Dupont AG: Iron status, iron supplementation and anemia in pregnancy: ethnic differences. J Matern Fetal Neonatal Med 2012;25:1305-1310.
- De la Cruz-Góngora V, Gaona B, Villalpando S, Shamah-Levy T, Robledo R: Anemia and iron, zinc, copper and magnesium deficiency in Mexican adolescents: National Health and Nutrition Survey 2006. Salud Publica Mex 2012;54:135-145.
- Cole CR, Grant FK, Swaby-Ellis ED, Smith JL, Jacques A, Northrop-Clewes CA, Caldwell KL, Pfeiffer CM, Ziegler TR: Zinc and iron deficiency and their interrelations in low-income African American and Hispanic children in Atlanta. Am J Clin Nutr 2010;91:1027-1034.
- Amor KT, Rashid RM, Mirmirani P: Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatol Online J 2010;16:3.
- Wu KJ, Polack A, Dalla-Favera R: Coordinated regulation of iron-controlling genes, H-ferritin and Irp2, by c-Myc. Science 1999;283:676-679.
- Waikel RL, Kawachi Y, Waikel PA, Wang XJ, Roop DR: Deregulated expression of c-Myc depletes epidermal stem cells. Nature Genet 2001;28:165-168.
- Elledge SJ, Zhou Z, Allen JB: Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992;17:119-123.
- Zheng Y, Prouty SM, Harmon A, Sundberg JP, Stenn KS, Parimoo S: Scd3 - a novel gene of the stearoyl-CoA desaturase family with restricted expression in skin. Genomics 2001;71:182-191.
- Bolland MJ, Ames RW, Grey AB, Horne AM, Mason BH, Gamble GD, Reid IR: Does degree of baldness influence vitamin D status? Med J Aust 2008;189:674-675.
- Demay MB: The hair cycle and vitamin D receptor. Arch Biochem Biophys 2012;523:19-21.
- Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-4396.
- Teichert A, Elalieh H, Bikle D: Disruption of the hedgehog signaling pathway contributes to the hair follicle cycling deficiency in VDR knockout mice. J Cell Physiol 2010;225:482-489.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.